The quantitative structure activity relationships for predicting HIV protease inhibition by substituted fullerenes

Letters in Drug Design and Discovery

Volumn 7, Issue 8, 2010, Pages 587-595

  Martin, Dana ^a   Karelson, Mati ^a  

^a UNIVERSITY OF TARTU   (Estonia)

Author keywords

HIV protease inhibition; QSAR; Substituted fullerenes

Indexed keywords

FULLERENE DERIVATIVE; PROTEINASE; PROTEINASE INHIBITOR;

ARTICLE; DRUG STRUCTURE; PREDICTION; PRIORITY JOURNAL; PROTEINASE INHIBITION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

EID: 77958495541     PISSN: 15701808     EISSN: None     Source Type: Journal    
DOI: 10.2174/157018010792062759     Document Type: Article

References (66)

1. NIAID-Division of AIDS. HIV/OI Therapeutics Database. http://chemdb2.niaid.nih.gov/struct_search/class/class_search.asp (accessed Oct 14, 2009).
2. De Clercq, E. Antiviral therapy for human immunodeficiency virus infections. Clin. Microbiol. Rev., 1995, 8, 200-238.
3. Hou, T.; Yu, R. Molecular dynamics and free energy studies on the wild-type and double mutant HIV-1 protease complexed with Amprenavir and two Amprenavir-related inhibitors: mechanism for binding and drug resistance. J. Med. Chem., 2007, 50, 1177-1188.
4. Navia, M.A.; Fitzgerald, P.M.D.; McKeever, B.M.; Leu, C.T.; Heimbach, J.C.; Herber, W.K.; Sigal, I.S.; Darke, P.L.; Springer, J.P. Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature, 1989, 337, 615-620.
5. Wlodawer, A.; Miller, M.; Jaskolski, M.; Sathyanarayana, B.K.; Baldwin, E.; Weber, I.T.; Selk, L.M.; Clawson, L.; Schneider, J.; Kent S.B. Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science, 1989, 245, 616-621.
6. Wlodawer, A.; Gustchina, A. Structural and biochemical studies of retroviral proteases. Biochem. Biophys. Acta, 2000, 1477, 16-34.
7. Lebon, F.; Ledecq, M. Approaches to the design of effective HIV-1 protease inhibitors. Curr. Med. Chem., 2000, 4, 455-477.
8. Klabe, R.M.; Bacheler, L.T.; Ala, P.J.; Erickson-Viitanen, S.; Meek, J.L. Resistance to HIV protease inhibitors: a comparison of enzyme inhibition and antiviral potency. Biochem., 1998, 37, 8735-8742.
9. Scholz, D.; Billich, A.; Charpiot, B.; Ettmayer, P.; Lehr, P.; Rosenwirth, B.; Schreiner, E.; Gstach, H. Inhibitors of HIV-1 proteinase containing 2-heterosubstituted 4-amino-3-hydroxy-5- phenylpentanoic acid: synthesis, enzyme inhibition, and antiviral activity. J. Med. Chem., 1994, 37, 3079-3089.
10. Tait, B.D.; Hagen, S.; Domagala, J.; Ellsworth, E.L.; Gajda, C.; Hamilton, H.W.; Prasad, J.V.N.V.; Ferguson, D.; Graham, N.; Hupe, D.; Nouhan, C.; Tummino, P.J.; Humblet, C.; Lunney, E.A.; Pavlovsky, A.; Rubin, J.; Gracheck, S.J.; Baldwin, E.T.; Bhat, T.N.; Erickson, J.W.; Gulnick, S.V.; Liu, B. 4-Hydroxy-5,6- dihydropyrones. 2. potent non-peptide inhibitors of hiv protease. J. Med. Chem., 1997, 40, 3781-3792.
11. Hagen, S.; Prasad, J.V.N.V.; Boyer, F.E.; Domagala, J.; Ellsworth, E.L.; Gajda, C.; Hamilton, H.W.; Markoski, L.J.; Steinbaugh, B.A.; Tait, B.D.; Lunney, E.A.; Tummino, P.J.; Fergusson, D.; Hupe, D.; Nouhan, C.; Gracheck, S.J.; Saunders, J.M.; VanderRoest, S. Synthesis of 5,6-dihydro-4-hydroxy-2- pyrones as HIV-1 protease inhibitors: the profound effect of polarity on antiviral activity. J. Med. Chem., 1997, 40, 3707-3711.
12. Boyer, F.E.; Prasad, J.V.N.V.; Domagala, J.M.; Ellsworth, E.L.; Gajda, C.; Hagen, S.; Markoski, L.J.; Tait, B.D.; Lunney, E.A.; Palovsky, A.; Fergusson, D.; Graham, N.; Holler, T.; Hupe, D.; Nouhan, C.; Tummino, P.J.; Urumov, A.; Zeikus, E.; Zeikus, G.; Gracheck, S.J.; Sanders, J.M.; VanderRoest, S.; Brodfuehrer, J.; Iyer, K.; Sinz, M.; Gulnik, S.V.; Erickson, J.W. 5,6-Dihydropyran-2- ones possessing various sulfonyl functionalities: potent nonpeptidic inhibitors of HIV protease. J. Med. Chem., 2000, 43, 843-858.
13. Hagen, S.; Domagala, J.; Gajda, C.; Lovdahl, M.; Tait, B.D.; Wise, E.; Holler, T.; Hupe, D.; Nouhan, C.; Urumov, A.; Zeikus, G.; Zei kus, E.; Lunney, E.A.; Pavlovsky, A.; Gracheck, S.J.; Saunders, J.; VanderRoest, S.; Brodfuehrer, J. 4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: the effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters. J. Med. Chem., 2001, 44, 2319-2332.
14. Garg, R.; Patel D. Hydrophobicity in the design of P2/P2' tetrahydropyrimidinone HIV protease inhibitors. Bioorg. Med. Chem. Lett., 2005, 15, 3767-3770.
15. Leonard, J. T.; Roy, K. QSAR by LFER of HIV protease inhibitor mannitol derivatives using FA-MLR, PCRA, and PLS techniques. Bioorg. Med. Chem., 2006, 14, 1039-1046.
16. Nunthanavanit, P.; Anthony, N.G.; Johnston, B.F.; Mackay, S.P.; Ungwitayatorn J. 3D-QSAR studies on chromone derivatives as HIV-1 protease inhibitors: application of Molecular Field Analysis. Arch. Pharm. Chem. Life Sci., 2008, 341, 357-364.
17. Yoshida, T.; Yamagishi, K.; Chuman, H. QSAR study of cyclic urea type HIV-1 PR inhibitors using ab initio MO calculation of their complex structures with HIV-1 PR. QSAR Comb. Sci., 2008, 27, 694-703.
18. Friedman, S.H.; DeCamp, D.L.; Sijbesma, R.P.; Srdanov, G.; Wudl, F.; Kenyon, G.L. Inhibition of the HIV-1 protease by fullerene derivatives: model building studies and experimental verification. J. Am. Chem. Soc., 1993, 115, 6506-6509.
19. Heymann, D. Solubility of fullerenes C60 and C70 in water. Lunar Planet Sci., 1996, 27, 542-543.
20. Sayes, C.M.; Fortner, J.D.; Guo, W.; Lyon, D.; Boyd, A.M.; Ausman, K.D.; Tao, Y.J.; Sitharaman, B.; Wilson, L.J.; Hughes, J.B.; West, J.L.; Corvin, V.L. The differential cytotoxicity of water- soluble fullerenes. Nano Lett., 2004, 4, 1881-1887.
21. Rancan, F.; Rosan, S.; Boehm F., Cantrell A., Brellreich M., Schoenberger H., Hirsch A., Moussa F. Cytotoxicity and photocytotoxicity of a dendritic C60 mono-adduct and a malonic acid C60 tris adduct on Jurkat cells. J. Photochem. Photobiol. B: Biology, 2002, 67, 157-162.
22. Hamano, T.; Okuda, K.; Mashino, T.; Hirobe, M.; Arakane, K.; Ryu, A.; Mashiko, S.; Nagano, T. Singlet oxygen production from fullerene derivatives: effect of sequential functionalization of the fullerene core. Chem. Commun., 1997, 21-22.
23. Schinazi, R.F.; Sijbesma, R.; Srdanov, G.; Hill, C.L.; Wudl, F. Synthesis and virucidal activity of a water-soluble, configurationally stable, derivatized C60 fullerene. Antimicrob. Agents Chemother., 1993, 37, 1707-1710.
24. Toniolo, C.; Bianco, A.; Maggini, M.; Scorrano, G.; Prato, M.; Marastoni, M.; Tomatis, R.; Spisani, S.; Palu, G.; Blair, E. D. A bioactive fullerene peptide. J. Med. Chem., 1994, 37, 4558-4562.
25. Nakamura, E.; Tokuyama, H.; Yamago, S.; Shiraki, T.; Sugiura, Y. Biological activity of water-soluble fullerenes. Structural dependence of DNA cleavage, cytotoxicity, and enzyme inhibitory activities including HIV-protease inhibition. Bull. Chem. Soc. Jpn., 1996, 69, 2143-2151.
26. Schuster, D.I.; Wilson, S.R.; Schinazi, R.F. Anti-human immunodeficiency virus activity and cytotoxicity of derivatized buckminsterfullerenes. Bioorg. Med. Chem. Lett., 1996, 11, 1253-1256.
27. Friedman, S.H.; Schinazi, R.F.; Wudl, F.; Hill, C.L.; DeCamp, D.L.; Sijbesma, R.P.; Kenyon, G.L. Water soluble fullerenes with antiviral activity. U.S. Patent 5, 811, 460, September 22, 1998.
28. Friedman, S.H.; Ganapathi, P.S.; Rubin, Y.; Kenyon, G.L. Optimizing the binding of fullerene inhibitors of the HIV-1 protease through predicted increases in hydrophobic desolvation. J. Med. Chem., 1998, 41, 2424-2429.
29. Bosi, S.; Da Ros, T.; Spalluto, G.; Balzarini, J.; Prato, M. Synthesis and anti-HIV properties of new water-soluble bisfunctionalized[ 60]fullerene derivatives. Bioorg. Med. Chem. Lett., 2003, 13, 4437-4440.
30. Friedman, S.H.; Schinazi, R.F.; Wudl, F.; Hill, C.L.; DeCamp, D.L.; Sijbesma, R.P.; Kenyon, G.L. Methods of treatment of viral infections including HIV using water soluble fullerenes-III. U.S. Patent 0044062 A1, March 4, 2004.
31. Marchesan, S.; Da Ros, T.; Spalluto, G.; Balzarini, J.; Prato, M. Anti-HIV properties of cationic fullerene derivatives. Bioorg. Med. Chem. Lett., 2005, 15, 3615-3618.
32. Mashino, T.; Shimotohno, K.; Ikegami, N.; Nishikawa, D.; Okuda, K.; Takahashi, K.; Nakamura, S.; Mochizuki, M. Human immunodeficiency virus-reverse transcriptase inhibition and hepatitis C virus RNA-dependent RNA polymerase inhibition activities of fullerene derivatives. Bioorg. Med. Chem. Lett., 2005, 15, 1107-1109.
33. Troshina, O.A.; Troshin, P.A.; Peregudov, A.S.; Kozlovskiy, V.I.; Balzarini, J.; Lyubovskaya, R.N. Chlorofullerene C60Cl6: a precursor for straightforward preparation of highly water-soluble polycarboxylic fullerene derivatives active against HIV. Org. Biomol. Chem., 2007, 5, 2783-2791.
34. Marcorin, G.L.; Da Ros, T.; Castellano, S.; Stefancich, G.; Bonin, I.; Miertus, S.; Prato, M. Design and synthesis of novel [60]fullerene derivatives as potential HIV aspartic protease inhibitors. Org. Lett., 2000, 25, 3955-3958.
35. Lee, V.S.; Nimmanpipug, P.; Aruksakunwong, O.; Promsri, S.; Sompornpisut, P.; Hannongbua, S. Structural analysis of lead fullerene-based inhibitor bound to human immunodeficiency virus type 1 protease in solution from molecular dynamics simulations. J. Mol. Graph. Modell., 2007, 26, 558-570.
36. Durdagi, S.; Mavromoustakos, T.; Chronakis, N.; Papadopoulos, M.G. Computational design of novel analogues as potential HIV-1 PR inhibitors: Analysis of the binding interactions between fullerene inhibitors and HIV-1 PR residues using 3D QSAR, molecular docking and molecular dynamic simulations. Bioorg. Med. Chem., 2008, 16, 9957-9974.
37. Durdagi, S.; Mavromoustakos, T.; Papadopoulos, M.G. 3D QSAR CoMFA/CoMSIA, molecular docking and molecular dynamics studies of fullerene-based HIV-1 PR inhibitors. Bioorg. Med. Chem. Lett., 2008, 18, 6283-6289.
38. Bosi, S.; Feruglio, L.; Da Ros, T.; Spalluto, G.; Gregoretti, B.; Terdoslavich, M.; Decorti, G.; Passamonti, S.; Moro, S.; Prato, M. Homolytic effects of water-soluble fullerene derivatives. J. Med. Chem., 2004, 47, 6711-6715.
39. Mashino, T.; Nishikawa, D.; Takahashi, K.; Usui, N.; Yamori, T.; Seki, M.; Endo, T.; Mochizuki, M. Antibacterial and antiproliferative activity of cationic fullerene derivatives. Bioorg. Med. Chem. Lett.; 2003, 13, 4395-4397.
40. Tsao, N.; Luh, T.Y.; Chou, C.K.; Chang, T.Y.; Wu, J.J.; Liu, C.C., Lei, H.Y. In vitro action of carboxyfullerene. J. Antimicrob. Chemother., 2002, 49, 641-649.
41. Tsao, N.; Luh, T.Y.; Chou, C.K.; Wu, J.J.; Lin, Y.S.; Lei, H.Y. Inhibition of group A Streptococcus infection by carboxyfullerene. Antimicrob. Ag. Chemother., 2001, 1788-1793.
42. Mashino, T.; Okuda, K.; Hirota, T.; Hirobe, M.; Nagano, T.; Mochizuki, M. Inhibition of E. coli growth by fullerene derivatives and inhibition mechanism. Bioorg. Med. Chem. Lett., 1999, 9, 2959-2962.
43. Bosi, S.; Da Ros, T.; Castellano, S.; Banfi, E.; Prato, M. Antimycobacterial activity of ionic fullerene derivatives. Bioorg. Med. Chem. Lett., 2000, 10, 1043-1045.
44. Tsao, N.; Kanakamma, P.P.; Luh, T.Y.; Chou, C.K.; Lei, H.Y. Inhibition of Escherichia coli-induced meningitis by carboxyfullerence. Antimicrob. Ag. Chemother., 1999, 2273-2277.
45. Jin, H.; Chem, W.Q.; Tang, X.W.; Chiang, L.Y.; Yang, C.Y.; Schloss, J.V. Polyhydroxylated C60, fullerenols, as glutamate receptor antagonists and neuroprotecive agents. J. Neurosci. Res., 2000, 62, 600-607.
46. Miller, G.G.; Kushch, A.A.; Romanova, V.S. Agent for inhibition of human immunodeficiency virus (HIV) and cytomegalovirus (CMV) infections and method of their inhibition. Russia Patent 2,196,602, January 20, 2003.
47. NIAID Home. Chemical. Therapeutical Class Search. http://chemdb.niaid.nih.gov/struct_search/class/class_many.asp?class=FULLERENES (accessed Oct 14, 2009).
48. Sengupta, D.; Verma, D.; Naik, P.K. Docking mode of delvardine and its analogues into the p66 domain of HIV-1 reverse transcriptase: screening using molecular mechanics-generalized born/surface area and absorption, distribution, metabolism and excretion properties. J. Biosci., 2007, 32(7), 1307-1316.
49. Mohamadi, F.; Richards, N.G.J.; Guida, W.C.; Liskamp, R.; Lipton, M.; Caufield, C.; Chang, G.; Hendrickson, T.; Still, W.C. Macromodel - an integrated software system for modeling organic and bioorganic molecules using molecular mechanics. J. Comput. Chem., 1990, 11, 440-467.
50. Jorgensen, W.L.; Maxwell, D.S.; Tirado-Rives, J. Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J. Am. Chem. Soc., 1996, 118, 11225-11236.
51. Dewar, M.J.S.; Zoebisch, E.G.; Healy, E.F.; Stewart, J.J.P. The development and use of quantum-mechanical molecular-models.76. AM1 - a new general-purpose quantum-mechanical molecularmodel. J. Am. Chem. Soc., 1985, 107, 3902-3909.
52. Stewart, J.J.P. MOPAC: a semiempirical molecular orbital program. J. Comput.-Aided. Mol. Des., 1990, 4, 1-103.
53. QSAR Model, Molcode, Ltd., Tartu, 2008.
54. Katritzky, A.R.; Lobanov, V.S.; Karelson, M. CODESSA, version 2.0, University of Florida, 1996.
55. Virtual Computational Chemistry Laboratory. http://vcclab.org/lab/alogps/ (accessed Oct 14 2009)
56. Draper, N.R.; Smith H. Applied Regression Analysis; John Wiley Sons: New York, 1966.
57. Katritzky, A.R.; Dobchev, D.A.; Fara, D.C.; Hür, E.; Tämm, K.; Kurunczi, L.; Karelson, M.; Varnek, A.; Solov'ev, V.P. Skin permeation rate as a function of chemical structure. J. Med. Chem., 2006, 49, 3305-3314.
58. Jonathan, P.; Krzanowski, W. J.; McCarthy W. V. On the use of cross-validation to assess performance in multivariate prediction. Stat. Comput., 2000, 10, 209-229.
59. 2=0.41. This low correlation indicates that the docking calculations do not fully explain the interactions between the substituted fullerenes and the HIV protease and alternative calculation methods should be tried for better explaining the inhibitory power of the substituted fullerenes towards HIV protease.
60. Katritzky, A.R.; Mu, L.; Lobanov, V.S.; Karelson, M. Correlation of boiling points with molecular structure. 1. A training set of 298 diverse organics and a test set of 9 simple inorganics. J. Phys. Chem., 1996, 100, 10400-10407.
61. Zhou, Z.; Parr, R.G. Activation hardness: new index for describing the orientation of electrophilic aromatic substitution. J. Am. Chem. Soc., 1990, 112, 5720-5724.
62. Zefirov, N.S.; Kirpichenov, M.A.; Izmailov, F.F.; Trofimov, M.I. Calculation schemes for atomic electronegativities in molecular graphs within the framework of Snderson's principle. Dokl Akad Nauk SSSR, 1987, 96, 883-887.
63. Katritzky, A.R.; Mu, L.; Karelson, M. A QSPR study of the solubility of gases and vapors in water. J. Chem. Inf. Comput. Sci., 1996, 36, 1162-1168.
64. Mulliken, R.S. Electronic population analysis on LCAO-MO molecular wave functions. J. Chem. Phys., 1955, 23, 1833-1840.
65. Stanton, D.T.; Jurs, P.C. Development and use of charged partial surface-area structural descriptors in computer-assisted quantitative structure property relationship studies. Anal. Chem., 1990, 62, 2323-2329.
66. Sannigrahi, A.B. Advanced Quantum Chemistry, 1992, vol. 23, p. 301.